scholarly journals Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

2019 ◽  
Vol 111 ◽  
pp. 59-67 ◽  
Author(s):  
John F. Greden ◽  
Sagar V. Parikh ◽  
Anthony J. Rothschild ◽  
Michael E. Thase ◽  
Boadie W. Dunlop ◽  
...  
PLoS ONE ◽  
2012 ◽  
Vol 7 (1) ◽  
pp. e29651 ◽  
Author(s):  
Zhang-Jin Zhang ◽  
Roger Ng ◽  
Sui Cheung Man ◽  
Tsui Yin Jade Li ◽  
Wendy Wong ◽  
...  

2021 ◽  
Author(s):  
Kia Watkins-Martin ◽  
Despina Bolanis ◽  
Stephane R. Devantoy ◽  
Marie-Helene Pennestri ◽  
Catherine Malboeuf-Hurtubise ◽  
...  

Background: While walking in nature has been shown to improve affect in adults from the community to a greater extent than walking in urban settings, it is unknown whether such findings can be generalized to individuals suffering from depression. Using a parallel group design, this randomized controlled trial examined the effects of a single walk in nature versus urban settings on negative and positive affect in adult psychiatric outpatients diagnosed with major depressive disorder (MDD). Method: Participants recruited from a psychiatric outpatient clinic for adults with MDD were randomly assigned to a nature or urban walk condition. Thirty-seven adults (mean age=49 years) completed a single 60-minute walk. Negative and positive affect were assessed using The Positive and Negative Affect Schedule or PANAS at 6 time points: before the walk, halfway during the walk, immediately post-walk, at home before bedtime, 24 hours post-walk, and 48 hours post-walk. Results: Controlling for baseline levels of affect before the walk, individuals who walked in nature experienced overall lower levels of negative affect, F(1, 35.039)=4.239, p=.047, compared to those who walked in urban settings. Positive affect did not differ across walk conditions. Limitations: The generalizability of results are limited by the small sample size and the presence of more female than male participants. Conclusions: Walking in nature might be a useful strategy to improve the affect of adults with MDD. Future research should investigate different ways to integrate the beneficial effects of nature exposure into existing treatment plans for psychiatric outpatients with MDD. Keywords: major depressive disorder (MDD); depression; nature; greenspace; affect; randomized-control trial; physical activity


2019 ◽  
Vol 16 (2) ◽  
pp. 232-238 ◽  
Author(s):  
Majid Anushiravani ◽  
Ali A. Manteghi ◽  
Ali Taghipur ◽  
Mahdi Eslami

Background: According to new studies, only 60% of depressed patients respond to pharmaceutical treatment while suffering from their side effects. Natural products as adjuvant or alternative therapies should be examined to find safer and more effective ways to cope with depression. Objective: To find out the potential benefits of a combined herbal drug based on Echium amoenum compared with citalopram in the treatment of Major Depressive Disorder. Design and Setting: In psychiatry clinics of Mashhad University of Medical Sciences, 50 patients who met the criteria for Major Depressive Disorder based on DSM-5 were studied in a parallel randomized controlled trial. Design and Setting: In psychiatry clinics of Mashhad University of Medical Sciences, 50 patients who met the criteria for Major Depressive Disorder based on DSM-5 were studied in a parallel randomized controlled trial. Intervention: Subjects were randomly assigned to receive Echium amoenum compound syrup (EACS) or citalopram tablet for 8 weeks. Outcome Measures: The efficacy of treatments and recurrence of disease were surveyed and compared according to Hamilton depression rating scale at weeks 0, 4, 8, 12. Results: Patients in both groups of citalopram and EACS showed remarkable reduction in scores of Hamilton questionnaire. At the eighth week of treatment, the mean scores in EACS group were significantly lower than citalopram group (p-value = 0.03). 52% of patients suffered from various complications in citalopram group while just 12% of patients in EACS group reported few complications. Conclusion: Clinical efficacy of this herbal drug was significantly higher than citalopram, and complications were also less and lower in EACS group. Further studies with larger groups and para-clinical assessments such as serologic tests and QEEG would improve our understanding of the impacts and mechanisms of EACS.


2021 ◽  
Vol 14 (1) ◽  
pp. 173-180
Author(s):  
LindaL. Carpenter ◽  
ScottT. Aaronson ◽  
Todd M. Hutton ◽  
Miriam Mina ◽  
Kenneth Pages ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document